Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer

Condition:   Gastric Cancer Intervention:   Diagnostic Test: 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT Sponsor:   Ruijin Hospital Recruiting
Source: - Category: Research Source Type: clinical trials

Related Links:

J Oncol. 2022 Jan 11;2022:9635218. doi: 10.1155/2022/9635218. eCollection 2022.ABSTRACTOBJECTIVE: To explore the application value of circulating tumor cells (CTCs) and circulating free DNA (cfDNA) from peripheral blood in the prognosis of advanced gastric cancer (AGC). Here, we measured CTCs and cfDNA quantity for predicting the outcome of patients. Patients and Methods. Forty-five patients with advanced gastric cancer who underwent neoadjuvant chemotherapy and surgical treatment were enrolled in this study. All patients received neoadjuvant chemotherapy with paclitaxel + S-1 + oxaliplatin (PSOX) regimen, and CTCs and cfD...
Source: Journal of Oncology - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Local and central FDG-SUV quantification and PET-response assessment showed high concordance. This confirms the accuracy of a PET-response-guided treatment algorithm for locally advanced oesophago-gastric junction cancer in a multicenter setting. Preoperative treatment adaptation revealed feasible and safe for patients.PMID:35035533 | PMC:PMC8753528 | DOI:10.1177/17588359211065153
Source: Adv Data - Category: Epidemiology Authors: Source Type: research
Source: Anti-Cancer Agents in Medicinal Chemistry - Category: Cancer & Oncology Authors: Tags: Articles Source Type: research
Conclusions Endoscopic evaluation was an independent preoperative factor to predict treatment response and prognosis in patients with GC after NAC. Endoscopic assessment may be especially valuable for patients who could not be assessed by RECIST. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents  |  Abstract  |  open access Full text
Source: Endoscopy International Open - Category: Gastroenterology Authors: Tags: Original article Source Type: research
ConclusionOur study is the first to discover that CECT radiomics could provide powerful and consistent predictions of therapeutic sensitivity to neoadjuvant chemotherapy among gastric cancer patients across different hospitals.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsBased on our preliminary experience, esophagectomy is safe and feasible following combined neoadjuvant immunotherapy with chemotherapy for locally advanced esophageal cancer.
Source: Esophagus - Category: Gastroenterology Source Type: research
This study aims to assess the impact of margin adequacy according to Japanese Gastric Cancer Association (JGCA) guidelines on overall survival (OS).PATIENTS AND METHODS: Patients who underwent surgery for stage I-III GAC at our institution between 2010 and 2017 were included. Margin adequacy according to JGCA, National Comprehensive Cancer Network (NCCN), and European Society for Medical Oncology (ESMO) guidelines was assessed, and their predictive value on OS was evaluated with Harrell's C-index. Patients were analyzed according to their margins' adherence to JGCA guidelines, and a propensity score matching (PSM) was run....
Source: Ann Oncol - Category: Cancer & Oncology Authors: Source Type: research
We present the updated recommendations of the French society for radiation oncology on radiotherapy of oesophageal cancer. Oesophageal cancer still remains a malignant tumour with a poor prognosis. Surgery remains the standard treatment for localized cancers, regardless of histology. For locally advanced stages, surgery remains a standard for adenocarcinomas after neoadjuvant treatment with chemotherapy or chemoradiotherapy. However, it is a therapeutic option after initial chemoradiotherapy for stage III squamous cell carcinomas, given the increased morbidity and mortality with a multimodal treatment, which results in an ...
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: Neoadjuvant nimotuzumab might provide no additional benefits to the treatment of gastric cancer.PMID:34918627 | DOI:10.1097/MD.0000000000027709
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Apatinib combined with DOS regimen is effective for patients with LAGC without significantly increasing adverse reactions. Meanwhile, tumor markers are reduced significantly. Besides, the Ro resection rate and the incidence of operative complications are obviously superior to the DOS neoadjuvant chemotherapy regimen alone.PMID:34912413 | PMC:PMC8613054 | DOI:10.12669/pjms.37.7.4265
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | Hospitals | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research